Rafael Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2024
June 14, 2024 at 04:01 pm EDT
Share
Rafael Holdings, Inc. reported earnings results for the third quarter and nine months ended April 30, 2024. For the third quarter, the company reported sales was USD 0.074 million compared to USD 0.071 million a year ago. Sales was USD 0.074 million compared to USD 0.071 million a year ago. Revenue was USD 0.336 million compared to USD 0.071 million a year ago. Net loss was USD 32.35 million compared to USD 1.44 million a year ago. Net loss was USD 32.35 million compared to USD 1.44 million a year ago. Basic loss per share from continuing operations was USD 1.36 compared to USD 0.06 a year ago. Basic loss per share from continuing operations was USD 1.36 compared to USD 0.06 a year ago. Basic loss per share was USD 1.36 compared to USD 0.06 a year ago. Basic loss per share was USD 1.36 compared to USD 0.06 a year ago.
For the nine months, sales was USD 0.21 million compared to USD 0.211 million a year ago. Sales was USD 0.21 million compared to USD 0.211 million a year ago. Revenue was USD 0.472 million compared to USD 0.211 million a year ago. Net loss was USD 29.94 million compared to USD 3.1 million a year ago. Net loss was USD 29.94 million compared to USD 3.1 million a year ago. Basic loss per share from continuing operations was USD 1.26 compared to USD 0.42 a year ago. Basic loss per share from continuing operations was USD 1.26 compared to USD 0.42 a year ago. Basic loss per share was USD 1.26 compared to USD 0.14 a year ago. Basic loss per share was USD 1.26 compared to USD 0.14 a year ago.
Rafael Holdings, Inc. is a holding company with interests in clinical and early-stage pharmaceutical companies. Its segments include Healthcare, Infusion Technology and Real Estate. The Healthcare segment holds interest in LipoMedix Pharmaceuticals Ltd. (LipoMedix), Barer Institute Inc. (Barer), Cornerstone Pharmaceuticals, Inc. (Cornerstone) and Rafael Medical Devices, LLC. The Real Estate segment consists of the Companyâs real estate holdings, which is comprised of a portion of a commercial building in Israel. The Infusion Technology segment holds interest in Day Three Labs, Inc. LipoMedix is a clinical-stage pharmaceutical company. Rafael Medical Devices, LLC, an orthopedic-focused medical device company. Cornerstone Pharmaceuticals, Inc. is a cancer metabolism-based therapeutics company. Cyclo Therapeutics Inc. develops Trappsol Cyclo, which is being evaluated in clinical trials for the treatment of Niemann-Pick Disease Type C1 (NPC).
RAFAEL HOLDINGS, INC. 
